Haematologica (Dec 2018)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

  • Meletios A. Dimopoulos,
  • Jesus San-Miguel,
  • Andrew Belch,
  • Darrell White,
  • Lotfi Benboubker,
  • Gordon Cook,
  • Merav Leiba,
  • James Morton,
  • P. Joy Ho,
  • Kihyun Kim,
  • Naoki Takezako,
  • Philippe Moreau,
  • Jonathan L. Kaufman,
  • Heather J. Sutherland,
  • Marc Lalancette,
  • Hila Magen,
  • Shinsuke Iida,
  • Jin Seok Kim,
  • H. Miles Prince,
  • Tara Cochrane,
  • Albert Oriol,
  • Nizar J. Bahlis,
  • Ajai Chari,
  • Lisa O’Rourke,
  • Kaida Wu,
  • Jordan M. Schecter,
  • Tineke Casneuf,
  • Christopher Chiu,
  • David Soong,
  • A. Kate Sasser,
  • Nushmia Z. Khokhar,
  • Hervé Avet-Loiseau,
  • Saad Z. Usmani

DOI
https://doi.org/10.3324/haematol.2018.194282
Journal volume & issue
Vol. 103, no. 12

Abstract

Read online

In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the effect on minimal residual disease and in clinically relevant subgroups. After 25.4 months of follow up, daratumumab plus lenalidomide/dexamethasone prolonged progression-free survival versus lenalidomide/dexamethasone alone (median not reached vs. 17.5 months; hazard ratio, 0.41; 95% confidence interval, 0.31-0.53; P